These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 33576380)

  • 1. Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart.
    Prakoso D; Lim SY; Erickson JR; Wallace RS; Lees JG; Tate M; Kiriazis H; Donner DG; Henstridge DC; Davey JR; Qian H; Deo M; Parry LJ; Davidoff AJ; Gregorevic P; Chatham JC; De Blasio MJ; Ritchie RH
    Cardiovasc Res; 2022 Jan; 118(1):212-225. PubMed ID: 33576380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoinositide 3-kinase (p110α) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction.
    Prakoso D; De Blasio MJ; Qin C; Rosli S; Kiriazis H; Qian H; Du XJ; Weeks KL; Gregorevic P; McMullen JR; Ritchie RH
    Clin Sci (Lond); 2017 Jun; 131(12):1345-1360. PubMed ID: 28487469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice.
    Makino A; Dai A; Han Y; Youssef KD; Wang W; Donthamsetty R; Scott BT; Wang H; Dillmann WH
    Am J Physiol Cell Physiol; 2015 Nov; 309(9):C593-9. PubMed ID: 26269457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes.
    Prakoso D; De Blasio MJ; Tate M; Kiriazis H; Donner DG; Qian H; Nash D; Deo M; Weeks KL; Parry LJ; Gregorevic P; McMullen JR; Ritchie RH
    Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H840-H852. PubMed ID: 32142359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E2f1 deletion attenuates infarct-induced ventricular remodeling without affecting O-GlcNAcylation.
    Dassanayaka S; Brittian KR; Jurkovic A; Higgins LA; Audam TN; Long BW; Harrison LT; Militello G; Riggs DW; Chitre MG; Uchida S; Muthusamy S; Gumpert AM; Jones SP
    Basic Res Cardiol; 2019 May; 114(4):28. PubMed ID: 31152247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-GlcNAc Transferase Promotes Compensated Cardiac Function and Protein Kinase A O-GlcNAcylation During Early and Established Pathological Hypertrophy From Pressure Overload.
    Zhu WZ; El-Nachef D; Yang X; Ledee D; Olson AK
    J Am Heart Assoc; 2019 Jun; 8(11):e011260. PubMed ID: 31131693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excessive
    Umapathi P; Mesubi OO; Banerjee PS; Abrol N; Wang Q; Luczak ED; Wu Y; Granger JM; Wei AC; Reyes Gaido OE; Florea L; Talbot CC; Hart GW; Zachara NE; Anderson ME
    Circulation; 2021 Apr; 143(17):1687-1703. PubMed ID: 33593071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardioprotective O-GlcNAc signaling is elevated in murine female hearts via enhanced O-GlcNAc transferase activity.
    Narayanan B; Sinha P; Henry R; Reeves RA; Paolocci N; Kohr MJ; Zachara NE
    J Biol Chem; 2023 Dec; 299(12):105447. PubMed ID: 37949223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy.
    Fricovsky ES; Suarez J; Ihm SH; Scott BT; Suarez-Ramirez JA; Banerjee I; Torres-Gonzalez M; Wang H; Ellrott I; Maya-Ramos L; Villarreal F; Dillmann WH
    Am J Physiol Regul Integr Comp Physiol; 2012 Oct; 303(7):R689-99. PubMed ID: 22874425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression of O-GlcNAc cycling enzymes in human breast cancers.
    Krześlak A; Forma E; Bernaciak M; Romanowicz H; Bryś M
    Clin Exp Med; 2012 Mar; 12(1):61-5. PubMed ID: 21567137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E2F1 Transcription Factor Regulates O-linked N-acetylglucosamine (O-GlcNAc) Transferase and O-GlcNAcase Expression.
    Muthusamy S; Hong KU; Dassanayaka S; Hamid T; Jones SP
    J Biol Chem; 2015 Dec; 290(52):31013-24. PubMed ID: 26527687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene and protein expression of O-GlcNAc-cycling enzymes in human laryngeal cancer.
    Starska K; Forma E; Brzezińska-Błaszczyk E; Lewy-Trenda I; Bryś M; Jóźwiak P; Krześlak A
    Clin Exp Med; 2015 Nov; 15(4):455-68. PubMed ID: 25315705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure.
    Lunde IG; Aronsen JM; Kvaløy H; Qvigstad E; Sjaastad I; Tønnessen T; Christensen G; Grønning-Wang LM; Carlson CR
    Physiol Genomics; 2012 Feb; 44(2):162-72. PubMed ID: 22128088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O-GlcNAc transferase affects the signal transduction of β1 adrenoceptor in adult rat cardiomyocytes by increasing the O-GlcNAcylation of β1 adrenoceptor.
    Cao H; Hu Y; Zhu X; Yao N; Gu J; Wang Y; Zhu W
    Biochem Biophys Res Commun; 2020 Jul; 528(1):71-77. PubMed ID: 32471715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feedback Regulation of
    Lin CH; Liao CC; Chen MY; Chou TY
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33801653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes-associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria.
    Banerjee PS; Ma J; Hart GW
    Proc Natl Acad Sci U S A; 2015 May; 112(19):6050-5. PubMed ID: 25918408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging roles of protein O-GlcNAcylation in cardiovascular diseases: Insights and novel therapeutic targets.
    Bolanle IO; Riches-Suman K; Williamson R; Palmer TM
    Pharmacol Res; 2021 Mar; 165():105467. PubMed ID: 33515704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained Increases in Cardiomyocyte Protein
    Ha CM; Bakshi S; Brahma MK; Potter LA; Chang SF; Sun Z; Benavides GA; He L; Umbarkar P; Zou L; Curfman S; Sunny S; Paterson AJ; Rajasekaran NS; Barnes JW; Zhang J; Lal H; Xie M; Darley-Usmar VM; Chatham JC; Wende AR
    J Am Heart Assoc; 2023 Oct; 12(19):e029898. PubMed ID: 37750556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OGT and OGA expression in postmenopausal skeletal muscle associates with hormone replacement therapy and muscle cross-sectional area.
    Toivonen MH; Pöllänen E; Ahtiainen M; Suominen H; Taaffe DR; Cheng S; Takala T; Kujala UM; Tammi MI; Sipilä S; Kovanen V
    Exp Gerontol; 2013 Dec; 48(12):1501-4. PubMed ID: 24365779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110α) signaling.
    De Blasio MJ; Huynh K; Qin C; Rosli S; Kiriazis H; Ayer A; Cemerlang N; Stocker R; Du XJ; McMullen JR; Ritchie RH
    Free Radic Biol Med; 2015 Oct; 87():137-47. PubMed ID: 25937176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.